Abstract: The invention provides a body-worn monitor featuring a processing system that receives a digital data stream from an ECG system. A cable houses the ECG system at one terminal end, and plugs into the processing system, which is worn on the patient's wrist like a conventional wristwatch. The ECG system features: i) a connecting portion connected to multiple electrodes worn by the patient; ii) a differential amplifier that receives electrical signals from each electrode and process them to generate an analog ECG waveform; iii) an analog-to-digital converter that converts the analog ECG waveform into a digital ECG waveform; and iv) a transceiver that transmits a digital data stream representing the digital ECG waveform (or information calculated from the waveform) through the cable and to the processing system. Different ECG systems, typically featuring three, five, or twelve electrodes, can be interchanged with one another.

Abstract: The invention broadly relates to the use of ?,?-unsaturated fatty acids to inhibit the filamentous growth of fungi and yeasts and to a method for producing same. In particular the invention relates to the use of optionally substituted C8 to C15 ?,?-unsaturated fatty acids or salts, esters or amides thereof for inhibiting or retarding the yeast-to-mycelium transition of organisms having a dimorphic life cycle.

Abstract: The invention provides methods for predicting, diagnosing or monitoring acute cardiac disorders, cardiac transplant rejection, or distinguishing acute cardiac disorders from pulmonary disorders, by measuring BNP signal peptide levels in a sample taken from a subject shortly after onset of, or presentation with the disorder or transplant rejection.

Abstract: The present invention relates to a new method for reversible staining and functional isolation or characterization of cells, e.g. antigen-specific T cells. With this technique, the original functional status of cells can be substantially maintained after their identification and purification. Thus, this new method is of broad benefit for basic research and clinical applications.

Abstract: The present invention provides Listeria that are attenuated for entry into non-phagocytic cells as well as a variety of methods of inducing immune responses involving administering compositions comprising the attenuated Listeria. Some of the attenuated Listeria are mutant Listeria that comprise at least one mutation in a gene encoding an invasin, such as an internalin. Some of the attenuated Listeria are further attenuated for cell-to-cell spread. Pharmaceutical compositions and vaccines useful in the methods of the invention are further provided. Methods of making and improving vaccines are also provided.

Abstract: The present invention relates to the production of a non-transgenic plant resistant or tolerant to a herbicide of the phosphonomethylglycine family, e.g., glyphosate. The present invention also relates to the use of a recombinagenic oligonucleobase to make a desired mutation in the chromosomal or episomal sequences of a plant in the gene encoding for 5-enol pyruvylshikimate-3-phosphate synthase (EPSPS). The mutated protein, which substantially maintains the catalytic activity of the wild-type protein, allows for increased resistance or tolerance of the plant to a herbicide of the phosphonomethylglycine family, and allows for the substantially normal growth or development of the plant, its organs, tissues or cells as compared to the wild-type plant irrespective of the presence or absence of the herbicide. Additionally the present invention relates to mutant E. coli cells that contain mutated EPSPS genes.

Abstract: A water pool with a cover that may be raised and lowered is presented herein. In one embodiment, the cover of the pool is a patio. In a further embodiment, the cover is raised and lowered by a lifting mechanism that is a hydraulic cylinder. A cover of a pool of the invention may be lowered to any point from the highest point to the lowest, providing a pool of variable depth at the discretion of the user.

Abstract: The invention provides a system for continuously monitoring a patient during hemodialysis. The system includes a hemodialysis machine for performing the hemodialysis process that features a controller, a pump, a dialyzer filter, a lumen, and an interface to a body-worn monitor. A patient attaches to the dialysis machine through the lumen, and wears a body-worn monitor for continuously measuring blood pressure. The monitor includes an optical system for measuring an optical waveform, an electrical system for measuring an electrical waveform, and a processing component for determining a transit time between the optical and electrical waveforms and then calculating a blood pressure value from the transit time. The body-worn monitor features an interface (e.g. a wired serial interface, or a wireless interface) to transmit the blood pressure value to the controller within the hemodialysis machine.

Abstract: The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases and conditions associated with aberrant levels of S1P.

Abstract: The invention provides a system and method for measuring vital signs (e.g. SYS, DIA, SpO2, heart rate, and respiratory rate) and motion (e.g. activity level, posture, degree of motion, and arm height) from a patient. The system features: (i) first and second sensors configured to independently generate time-dependent waveforms indicative of one or more contractile properties of the patient's heart; and (ii) at least three motion-detecting sensors positioned on the forearm, upper arm, and a body location other than the forearm or upper arm of the patient. Each motion-detecting sensor generates at least one time-dependent motion waveform indicative of motion of the location on the patient's body to which it is affixed.

Abstract: The invention provides a body-worn monitor that measures a patient's vital signs (e.g. blood pressure, SpO2, heart rate, respiratory rate, and temperature) while simultaneously characterizing their activity state (e.g. resting, walking, convulsing, falling). The body-worn monitor processes this information to minimize corruption of the vital signs by motion-related artifacts. A software framework generates alarms/alerts based on threshold values that are either preset or determined in real time. The framework additionally includes a series of ‘heuristic’ rules that take the patient's activity state and motion into account, and process the vital signs accordingly. These rules, for example, indicate that a walking patient is likely breathing and has a regular heart rate, even if their motion-corrupted vital signs suggest otherwise.

Abstract: Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described.

Abstract: Methods of assaying for disease-associated crystal species in biological samples are described. Such methods involve contacting a patient sample with an excess of a detectable crystal-tagging compound reactive with a plurality of crystal species under conditions that allow the detectable crystal-tagging compound to react with a plurality of crystal species, if present, to form tagged crystal species complexes. Substantially all unreacted tagging compound is then removed. If desired, chemical, enzymatic, or physical treatment can be used to selectively degrade some, but not, of the tagged crystal species. Assessment of soluble versus crystal-associated label is then performed.

Abstract: Headlights wherein one or more parameters associated with the illumination provided by the associated light source are described. Parameters that can be adjusted, for example, include the intensity of light exiting the headlight assembly, the dispersion of light emitted from the headlight, the direction of illumination, and the like.

Abstract: The present invention relates to recombinant chimeric proteins comprising a surfactant protein precursor N-terminally fused to a plasminogen activator or comprising a mature surfactant protein N-terminally or C-terminally fused to a plasminogen activator. The invention is also directed to the corresponding nucleic acid molecules encoding such fusion proteins as well as to a method for their production. The invention further refers to a pharmaceutical composition comprising such a fusion protein and to pharmacological uses of an inventive fusion protein for the prevention and/or treatment of inflammatory and interstitial lung diseases.

Abstract: Containers for incrementally dispensing pressurized contents are described. The containers comprise a vessel suited to contain pressurized contents, a port integral with the vessel and through which pressurized contents contained in the vessel can be released from the vessel, preferably incrementally in approximately equal amounts, and a measuring device disposed in or otherwise associated with the vessel such that the quantity or amount of contents in the vessel can be measured or assessed. The measuring device senses ambient conditions in the vessel and, directly or with other components, indicates, for example, the amount of pressurized contents remaining in the vessel and displaying it to an observer. Devices for incrementally dispensing pressurized contents from such containers are also described.

Abstract: Automated methods and systems for the detection and analysis of plaque in one or more regions of a patient's vasculature are described.

Abstract: The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases and conditions associated with aberrant levels of S1P.

Abstract: Electrocardiogram (ECG) recorded signals are processed by a computer-implemented method to substantially remove extraneous signals to produce intermediary signals, and to separate the intermediary signals using a non-orthogonal transformation method such as independent component analysis to produce independent components of signals. The separated signals are displayed to help physicians to analyze medical conditions and to identify locations of abnormal heart conditions.

Abstract: The present invention relates to anti-S1P agents, for example, humanized monoclonal antibodies, and their uses for detection of S1P or for treatment of diseases and conditions associated with S1P.